Clinuvel Pharmaceuticals Stock Net Income
| CLVLF Stock | USD 8.45 0.03 0.36% |
As of the 5th of February, Clinuvel Pharmaceuticals shows the Standard Deviation of 1.87, mean deviation of 0.7722, and Risk Adjusted Performance of 0.1283. Clinuvel Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Clinuvel Pharmaceuticals coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Clinuvel Pharmaceuticals is priced correctly, providing market reflects its regular price of 8.45 per share. Given that Clinuvel Pharmaceuticals has total risk alpha of 0.1623, we suggest you to validate Clinuvel Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.
Clinuvel Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Clinuvel Pharmaceuticals' valuation are provided below:Clinuvel Pharmaceuticals does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Clinuvel |
Clinuvel Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Clinuvel Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Clinuvel Pharmaceuticals.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Clinuvel Pharmaceuticals on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Clinuvel Pharmaceuticals or generate 0.0% return on investment in Clinuvel Pharmaceuticals over 90 days. Clinuvel Pharmaceuticals is related to or competes with Frontage Holdings, Immutep, Northwest Biotherapeutics, Cytodyn, PureTech Health, Cellectis, and Healios KK. Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for ... More
Clinuvel Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Clinuvel Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Clinuvel Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1317 | |||
| Maximum Drawdown | 14.74 | |||
| Potential Upside | 1.75 |
Clinuvel Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clinuvel Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Clinuvel Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Clinuvel Pharmaceuticals historical prices to predict the future Clinuvel Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1283 | |||
| Jensen Alpha | 0.3296 | |||
| Total Risk Alpha | 0.1623 | |||
| Treynor Ratio | (0.57) |
Clinuvel Pharmaceuticals February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1283 | |||
| Market Risk Adjusted Performance | (0.56) | |||
| Mean Deviation | 0.7722 | |||
| Coefficient Of Variation | 601.65 | |||
| Standard Deviation | 1.87 | |||
| Variance | 3.5 | |||
| Information Ratio | 0.1317 | |||
| Jensen Alpha | 0.3296 | |||
| Total Risk Alpha | 0.1623 | |||
| Treynor Ratio | (0.57) | |||
| Maximum Drawdown | 14.74 | |||
| Potential Upside | 1.75 | |||
| Skewness | 3.31 | |||
| Kurtosis | 15.77 |
Clinuvel Pharmaceuticals Backtested Returns
Clinuvel Pharmaceuticals appears to be not too volatile, given 3 months investment horizon. Clinuvel Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.13, which signifies that the company had a 0.13 % return per unit of risk over the last 3 months. We have found twenty technical indicators for Clinuvel Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please makes use of Clinuvel Pharmaceuticals' Risk Adjusted Performance of 0.1283, standard deviation of 1.87, and Mean Deviation of 0.7722 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Clinuvel Pharmaceuticals holds a performance score of 10. The firm shows a Beta (market volatility) of -0.53, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Clinuvel Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Clinuvel Pharmaceuticals is likely to outperform the market. Please check Clinuvel Pharmaceuticals' jensen alpha, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Clinuvel Pharmaceuticals' price patterns will revert.
Auto-correlation | 0.68 |
Good predictability
Clinuvel Pharmaceuticals has good predictability. Overlapping area represents the amount of predictability between Clinuvel Pharmaceuticals time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Clinuvel Pharmaceuticals price movement. The serial correlation of 0.68 indicates that around 68.0% of current Clinuvel Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.68 | |
| Spearman Rank Test | 0.72 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Clinuvel Pharmaceuticals reported net income of 20.88 M. This is 93.88% lower than that of the Healthcare sector and 70.19% lower than that of the Biotechnology industry. The net income for all United States stocks is 96.34% higher than that of the company.
Clinuvel Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clinuvel Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Clinuvel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Clinuvel Pharmaceuticals by comparing valuation metrics of similar companies.Clinuvel Pharmaceuticals is currently under evaluation in net income category among its peers.
Clinuvel Fundamentals
| Return On Equity | 0.19 | |||
| Return On Asset | 0.18 | |||
| Profit Margin | 0.32 % | |||
| Operating Margin | 0.54 % | |||
| Current Valuation | 635.56 M | |||
| Shares Outstanding | 49.41 M | |||
| Shares Owned By Insiders | 20.55 % | |||
| Shares Owned By Institutions | 8.77 % | |||
| Price To Earning | 34.88 X | |||
| Price To Book | 8.27 X | |||
| Price To Sales | 10.65 X | |||
| Revenue | 65.72 M | |||
| Gross Profit | 56.92 M | |||
| EBITDA | 37.35 M | |||
| Net Income | 20.88 M | |||
| Cash And Equivalents | 121.51 M | |||
| Cash Per Share | 2.46 X | |||
| Total Debt | 1.26 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 10.24 X | |||
| Book Value Per Share | 2.54 X | |||
| Cash Flow From Operations | 39.87 M | |||
| Earnings Per Share | 0.28 X | |||
| Number Of Employees | 11 | |||
| Beta | 0.82 | |||
| Market Capitalization | 835.03 M | |||
| Total Asset | 143.95 M | |||
| Retained Earnings | (133 M) | |||
| Working Capital | 18 M | |||
| Current Asset | 20 M | |||
| Current Liabilities | 2 M | |||
| Annual Yield | 0 % | |||
| Net Asset | 143.95 M | |||
| Last Dividend Paid | 0.04 |
About Clinuvel Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clinuvel Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clinuvel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clinuvel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Clinuvel Pink Sheet
Clinuvel Pharmaceuticals financial ratios help investors to determine whether Clinuvel Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Clinuvel with respect to the benefits of owning Clinuvel Pharmaceuticals security.